News & Analysis as of

Purdue Pharma Patent Litigation

Sheppard Mullin Richter & Hampton LLP

PTAB’s Authority to Issue a Final Written Decision After a Statutory Deadline

In Purdue Pharma L.P. v. Collegium Pharmaceutical, Inc. 2022-1482 (Fed. Cir. Nov. 21, 2023), the case addresses the Patent Trial and Appeal Board’s (“PTAB’s”) authority to issue a Final Written Decision in a post grant review...more

Knobbe Martens

Federal Circuit Review - November 2023

Knobbe Martens on

Federal Circuit Orders District Court to Consider Extrinsic Evidence in Claim Construction - In Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc., Appeal No. 22-1889, the Federal Circuit held that where a...more

WilmerHale

Federal Circuit Patent Watch: Avoid fighting with the courts and administrative agencies

WilmerHale on

Precedential and Key Federal Circuit Opinions - 1.  PURDUE PHARMA LP v. COLLEGIUM PHARMACEUTICAL, INC. [OPINION] (2022-1482, 11/21/2023) (Dyk, Hughes, and Stoll) - Dyk, J. The Court affirmed the Patent Trial and...more

Smart & Biggar

Supreme Court of Canada denies Amgen leave to appeal decision invalidating its filgrastim patent

Smart & Biggar on

As previously reported, Amgen sought leave to appeal a decision of the Federal Court of Appeal (2020 FCA 188) affirming Justice Southcott’s decision that the relevant claims of its filgrastim (NEUPOGEN) patent were invalid...more

4 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide